Align Technology, Inc. (ALGN) fair value analysis

S&P 500 & Nasdaq · Updated 2026-09-07

Align Technology, Inc. manufactures and sells clear aligner systems and other orthodontic products used to straighten teeth, along with digital scanning and treatment planning software for dental professionals. The company operates globally, serving orthodontists, general dentists, and patients across multiple countries through direct sales and distribution channels.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ALGN is trading at more than a 25% discount to estimated fair value.

ALGN currently ranks #10 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $158.63
Sector: Healthcare
12-month range: $137.88–$189.02

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
Margin trend: Stable
Revenue growth: Modest
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range
DCF cross-check: Overvalued

What our data shows for ALGN

Our model validated 17 trailing price-to-earnings windows for ALGN, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $137.88–$189.02.
The 14-day relative strength index sits at a neutral 39.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ALGN
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent ALGN news

TickrTrends' derived news-sentiment signal for ALGN is currently mixed, computed from recent coverage.

Align Technology (ALGN) Appoints Quentin Blackford to Board of Directors (gurufocus.com, 2026-09-01)
TickrTrends take: Align Technology's appointment of Quentin Blackford to its board represents a governance development that may influence how investors assess the company's strategic direction and oversight quality. Given TickrTrends' current undervalued assessment of ALGN, observers should monitor whether new board composition affects capital allocation decisions, operational efficiency, or competitive positioning within the Healthcare sector. Board additions can signal management's confidence in company strategy or indicate shifts in priorities that could eventually impact the fundamental value drivers underlying the valuation analysis.
Are Wall Street Analysts Bullish on Align Technology Stock? (finance.yahoo.com, 2026-08-27)
TickrTrends take: Align Technology operates in the Healthcare sector, where the TickrTrends valuation model currently indicates the stock is undervalued. A valuation-focused reader should monitor whether Wall Street analyst sentiment becomes reflected in price movement, as bullish analyst positioning could either validate the undervaluation thesis or narrow the gap between current price and intrinsic value estimates. The relationship between analyst optimism and the company's fundamental valuation metrics will be particularly relevant for determining whether the current undervalued designation persists.
Align Technology: DCF Signals Overvaluation Despite Long-Term Growth Potential (seekingalpha.com, 2026-08-17)
TickrTrends take: Align Technology trades in a sector where valuation assessments can diverge significantly based on methodology, as evidenced by the tension between DCF analysis flagging overvaluation concerns and TickrTrends' undervalued classification. For investors focused on valuation metrics, this discrepancy suggests monitoring the company's ability to convert its stated long-term growth potential into near-term cash flow generation, as the gap between these perspectives will likely narrow as actual results emerge. The healthcare sector's growth dynamics mean that execution on expansion plans will be critical to determining which valuation framework proves more accurate over time.

What people are saying

Follow the ALGN conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — ALGN's momentum indicator downgraded from B to none this week, suggesting a weakening in price movement strength. The stock maintains an undervalued position according to TickrTrends' valuation assessment, despite the shift in its momentum rating.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ALGN stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ALGN is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ALGN's TickrTrends verdict?

ALGN's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ALGN compare to other Healthcare stocks?

ALGN ranks #10 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ALGN overbought or oversold?

ALGN's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ALGN vs ADMA · ALGN vs AMPH · ALGN vs ANIP · ALGN vs ASTH · ALGN vs AZN